#Israel #Petah Tikva #Heart Failure #Microtech #Medinol

Microtech's Innovative Step in Heart Failure Treatment

Leading medtech innovator Microtech, a wholly owned subsidiary of Medinol, Inc., has made a significant leap in cardiac care by initiating clinical trials for their groundbreaking implantable microsensors designed to monitor atrial pressure, a crucial aspect in heart failure management. This milestone was marked by the first successful implantation conducted by Professor Erez Sharoni at Beilinson Medical Center in Petah Tikva, Israel.

Microtech's implantable microsensor technology is the culmination of decades of research aimed at creating compact sensors that can function independently or integrate with existing medical devices. These sensors are notably smaller than one millimeter and utilize passive technology with ultrasonic external communication. This has the potential to transform traditional medical implants into intelligent devices that collect comprehensive data while performing various functions.

Professor Sharoni, who is also the head of the cardiac and thoracic surgery department, emphasized the impact of this technology on patient care standards for heart failure, particularly for individuals relying on Left Ventricular Assist Devices (LVADs) or heart transplants. “This revolutionary technology can change the care paradigm for heart failure patients,” he remarked.

Data captured by the implanted sensors will be aggregated, providing heart failure specialists with valuable information to make informed decisions concerning patient care. Dr. Tuvia Ben-Gal, head of the heart failure treatment department at Rabin Medical Center, pointed out that heart failure often features periods of stability followed by exacerbations, necessitating repeated hospitalizations. “This groundbreaking technology will allow us to monitor patient parameters in real-time, enabling earlier intervention to reduce morbidity and mortality,” he noted.

The integration of sensors with existing devices empowers physicians to treat patients based on objective physiological parameters rather than solely on symptoms, marking a significant progress towards equitable healthcare access globally. According to Dr. Yoram Richter, CEO of Medinol, patients with implants featuring Microtech technology can relay precise blood pressure data directly to their healthcare providers, effectively eliminating geographic barriers and mobility challenges.

“This exceptional capability will fundamentally change numerous clinical scenarios. It will benefit not only heart failure patients but also those with glaucoma, hydrocephalus, portal hypertension, abdominal aortic aneurysms (AAA), and various other conditions. It enhances access to healthcare while reducing the necessity for doctor visits and hospitalizations,” he elaborated.

The implications of intelligent devices equipped with sensors extend far beyond emergency corrections of anatomical abnormalities; they encompass lifelong treatment for patients. Medinol’s commitment to transform disease diagnosis and management through innovative medical devices is evident in their development of advanced stents and real-time physiological data monitoring through implantable sensors, effectively modernizing existing technologies and procedures.

With a focus on building a better future for healthcare, Medinol continues to partner with healthcare providers and industry stakeholders to push the boundaries of medical technology. For more details on this transformative initiative, visit Medinol's website or contact Jeff Roache, Chief Commercial Officer, at [email protected]